Journals / Turkish Neurosurgery / 2015 / Cilt: 25 - Sayı: 3

Cavernous Sinus Invasion and Effect of Immunohistochemical Features on Remission in Growth Hormone Secreting Pituitary Adenomas

Büyüme Hormonu Salgılayan Hipofiz Adenomlarmda Kavernöz Sinüs İnwazyonu we İmmünohistokimyasal Özelliklerin Remisyona Etkisi

Pages
380–388
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

VEGF expression can therefore indirectly affect remission via cavernous sinus invasion.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:AIM: We examined the cavernous sinus invasion and tumor biological markers that influence the remission rate.
📊
Key Findings & Data:Tumor biological markers consisting of the tumor cell growth parameter Ki-67 and the cancer cell vasculature marker of vascular endothelial growth factor (VEGF) were evaluated.
💡
Conclusion & Impact:VEGF expression can therefore indirectly affect remission via cavernous sinus invasion.
🔬Design:Research Article
📍Scope:2003 Verileri
⚙️Variables:Domain Parameters

Abstract

AIM: We examined the cavernous sinus invasion and tumor biological markers that influence the remission rate. Cavernous sinus (CS) invasion was evaluated radiologically. Tumor biological markers consisting of the tumor cell growth parameter Ki-67 and the cancer cell vasculature marker of vascular endothelial growth factor (VEGF) were evaluated. MATErIAL and METHods: We examined 28 immunohistochemically proven GH secreting pituitary adenoma patients who had been operated via endoscopic transsphenoidal surgery at Department of Neurosurgery, Kocaeli University Hospital between 2003 and 2008. Pathology preparations were stained with Ki-67 and VEGF. We evaluated remission at the postoperative 6th week. The basal GH level, nadir GH level and IGF-1 levels were evaluated to determine remission. rEsuLTs: Remission was achieved in 6 of 18 patients (33%) who had cavernous sinus invasion. Remission was achieved in 7 of 10 patients (70%) who did not have cavernous sinus invasion. There was no correlation between the Ki-67 proliferation index and cavernous sinus invasion (p=0.593). There was a positive correlation between VEGF expression and cavernous sinus invasion (p=0.03). CoNCLusIoN: The remission rate found less in the cavernous sinus invasion group. No association was found between Ki 67 proliferation index and cavernous sinus invasion. We found that a positive correlation between VEGF expression and cavernous sinus invasion. VEGF expression can therefore indirectly affect remission via cavernous sinus invasion.

Özet

AMAÇ: Çalışmada remisyona etkisi olduğu öngörülen faktörlerden; kavernöz sinüs invazyonu ve tümör biyolojisi ile ilgili özellikler gözden geçirildi. Bu amaçla kavernöz sinüs invazyonu radyolojik olarak değerlendirildi. Ayrıca tümör biyolojisini gösteren; tümör büyüme potansiyelinde etkili Ki-67 ve tümör damarlanmasını gösteren VEGF immünohistokimyasal olarak incelendi. yÖNTEM ve GErEÇLEr: Çalışmaya 2003-2008 tarihleri arasında Kocaeli Üniversitesi Hastanesi Nöroşirürji Kliniği'nde endoskopik transfenoidal yolla ameliyat edilen 28 büyüme hormonu (GH) adenomu hastası dahil edildi. Doku örneklerine Ki-67 ve VEGF immünohistokimyasal boyamaları uygulandı. Kısa dönem remisyon değerlendirmesi için postoperatif 6. haftada IGF-1 ve OGTT sonrası GH düzeyleri ölçümlerine bakıldı. BuLGuLAr: Kavernöz sinüs invazyonu olan hastalarda kısa dönem remisyon oranı 6/18 (%33) idi. Kavernöz sinüs invazyonu olmayan 10 hastanın 7'sinde remisyon sağlandı (%70). Ki-67 proliferasyon indeksi ile kavernöz sinüs invazyonu arasında anlamlı bir korelasyon olmadığı (p=0,593), VEGF ekspresyonunun kavernöz sinüs invazyonu açısından önemli bir gösterge olduğu (p=0,03) saptandı. soNuÇ: Kavernöz sinüs invazyonu gösteren GH adenomu olgularında kısa dönem remisyon oranlarının daha düşük görüldüğü, Ki-67'nin kavernöz sinüs invazyonu ve remisyonu etkilemediği, VEGF ekspresyonunun kavernöz sinüs invazyonunu artırarak indirekt yolla remisyon üzerinde etkili olabileceği sonucuna varıldı.

🔖

Cite This Article

YILMAZ, M., CEYLAN, S., KOC, K., VURAL, E. (2022). Cavernous Sinus Invasion and Effect of Immunohistochemical Features on Remission in Growth Hormone Secreting Pituitary Adenomas. Turkish Neurosurgery, Cilt: 25 - Sayı: 3, 380–388. https://ajindex.com/articles/616971

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Ahmadi J, North CM, Segall HD, Zee CS, Weiss MH: Cavernous sinus invasion by pituitary adenomas. AJR Am Roentgenol 146: 257-262, 1986
  2. Bates AS, Van't Hoff W, Jones JM, Clayton RN: An audit of outcome of treatment in acromegaly. Quarterly Journal of Medicine 86: 293-299, 1993
  3. Beauregard C, Truong U, Hardy J, Serri O: Long-term outcome and mortality after transsphenoidal adenomectomy for acromegaly. Clin Endocrinol (Oxf) 58: 86-91, 2003
  4. Bergers G, Benjamin LE: Tumorigenesis and the angiogenic switch. Nat Rev Cancer 3: 401 -41 0, 2003 Biermasz NR, van Dulken H, Roelfsema F: Ten-year follow-up results of transsphenoidal microsurgery in acromegaly.J Clin Endocrinol Metab 85: 4596-602, 2000
  5. Bochner BH, Cote RJ, Weidner N, Groshen S, Chen SC, Skinner DG, Nichols PW: Angiogenesis in bladder cancer: Relationship between microvessel density and tumor prognosis. Natl Cancer Inst 87: 1603-1612, 1995
  6. Bochner BH, Cote RJ, Weidner N, Groshen S, Chen SC, Skinner DG, Nichols PW: Expression of vascular permeability factor (vascular endothelial growth factor and its receptors in breast cancer. Hum Pathol 26:86-91, 1995
  7. Botelho CH, Magalhaes AV, Mello PA, Schmitt FC, Casulari LA: Expression of p53, Ki-67 and c-erb B2 in growth hormone and/or prolactin-secreting pituitary adenomas. Arq Neuropsiquiatr 64(1):60-66, 2006
  8. Cottier JP, Destrieux C, Brunereau L, Bertrand P, Moreau L, Jan M, Herbreteau D: Cavernous sinus invasion by pituitary adenoma: MR imaging. Radiology 215:463--469, 2000
  9. De P, Rees DA, Davies N, John R, Neal J, Mills RG, Vafidis J, Davies JS, Scanlon MF: Transsphenoidal surgery for acromegaly in Wales: Results based on stringent criteria of remission.J Clin Endocrinol Metab 88: 3567-3572, 2003 Dolenc VV: Anatomy and surgery of the cavernous sinus. Yugoslavia: Springer, Verlag/Wien, 1989.Falbusch R, Buchfejder M: Transsphenoidal surgery of parasellar pituitary adenomas. Acta Neu rochir 92:93-99, 1988
  10. Ferrara N, Gerber HP, LeCouter J:The biology ofVEGF and its receptors. Nat Med 9: 669-676, 2003
  11. Folkman J, Shing Y: Angiogenesis. Biol Chem 267: 10931- 10934, 1992
  12. Freda PU, Wardlaw SL, Post KD: Long-term endocrinological follow-up evaluation in 115 patients who underwent transsphenoidal surgery for acromegaly.J Neurosurg 89: 353- 358,1998.Garcia de la Torre N, Wass JA, Turner HE: Antiangiogenic effects of somatostatin analogues. Clin Endocrinol (Oxf) 57: 425- 441, 2002
  13. Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H: Cell cycle analysis of cell proliferati